Headache
-
The following article from Headache: The Journal of Head and Face Pain, "Prevalence and Burden of Headache Disorders: A Comparative Regional Study in China," by Ning Luo PhD, Yannan Fang PhD, Feng Tan MD, Qian Zhang MD, Daliang Zou MD, Xiutang Cao PhD, Xuehua Xu MD, Hua Bai MD, Jiangang Ou MD, Haike Wu MD, Zilong Chen MD, Yane Zhou MD, Saiying Wan MD, Yan Hong MD, Jingliang Wang MD, Minghui Ding MD, Aiwu Zhang PhD, Daoyuan Zhu MD, Jun Dun PhD, published online on November 10, 2010 (DOI: 10.1111/j.1526-4610.2010.01795.x) on Wiley Online Library (http://www.onlinelibrary.wiley.com), has been retracted per agreement between the authors, the journal's Editor-in-Chief, John F. Rothrock, and Wiley Periodicals, Inc. This retraction has been made due to the article having been erroneously submitted to the journal prematurely in non-final form and without all authors having agreed to publication.
-
Observational Study
Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study.
We sought to assess the safety and tolerability of 3 calcitonin gene-related peptide (CGRP) monoclonal antibodies in patients with chronic migraine who have failed multiple classes of migraine preventive therapies. ⋯ In patients with chronic migraine, the 3 CGRP monoclonal antibodies were well tolerated, and reduced the number of severe headache days.
-
Randomized Controlled Trial
Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies.
This post hoc analysis evaluated the efficacy of galcanezumab for the prevention of migraine in patients with and without comorbid anxiety and/or depression. ⋯ A medical history of anxiety and/or depression does not seem to interfere with response to galcanezumab among patients with episodic migraine, and both doses of galcanezumab appear efficacious for these individuals regardless of this psychiatric history. Among patients with chronic migraine and comorbid anxiety and/or depression, the 240-mg dose, but not the 120-mg dose, significantly decreased overall MHD, but neither dose resulted in significantly greater functional improvement. Patients with migraine and comorbid anxiety and/or depression often require additional interventions, and this may be more important in chronic migraine.
-
To evaluate the efficacy and complications of C2 dorsal root ganglion (DRG) pulsed radiofrequency ablation (RFA) for cervicogenic headache (CEH) and to identify factors related to the outcome of the procedure in this retrospective analysis. ⋯ C2 DRG pulsed RFA may be an effective treatment for patients with CEH, particularly for patients who have previously experienced definite pain reduction after C2 DRG block. However, the limitations of our study design and small number of patients preclude firm conclusions.
-
Headache attributed to airplane travel is a rare form of headache that develops exclusively during airplane travel. It is characterized by occurring during takeoff, landing, or both, and improves spontaneously within 30 minutes after the ascent or descent of the airplane is completed. ⋯ This study demonstrated that headache attributed to airplane travel is not as rare as previously thought, being predominant during takeoff or landing. In addition, despite the bothersome feeling, most passengers who experienced this headache traveled normally, despite previous painful experience.